blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2886544

EP2886544 - Process for the preparation of crystalline sitagliptin fumarate [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.09.2019
Database last updated on 15.01.2025
FormerThe patent has been granted
Status updated on  19.10.2018
FormerGrant of patent is intended
Status updated on  30.08.2018
FormerExamination is in progress
Status updated on  04.07.2018
FormerGrant of patent is intended
Status updated on  27.02.2018
FormerExamination is in progress
Status updated on  19.05.2017
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1
Western Express Highway, Goregaon (E)
400 063 Mumbai
MAH / IN
[2016/17]
Former [2015/26]For all designated states
Ranbaxy Laboratories Limited
12th Floor, Devika Tower 06, Nehru Place
New Delhi 110019 / IN
Inventor(s)01 / Shah, Jigar Bhaskarbhai
B-753, Tumdi Street
Sonari Mahal
392001 Bharuch, Gujarat / IN
02 / Kanawade, Sandeep T.
At/P: Rajur, TAL: Akole
422604 Ahmednagar, Maharashtra / IN
03 / Jayachandra, Suresh Babu
82, Green Avenues
Nizampet Road, Kukatpally
500072 Hyderabad, Andhra Pradesh / IN
 [2015/26]
Representative(s)Cronin, Brian Harold John
c/o Gsmart IP SA
Route de Florissant 81
1206 Genève / CH
[N/P]
Former [2015/26]Cronin, Brian Harold John
CRONIN Intellectual Property Chemin de Précossy 31
1260 Nyon / CH
Application number, filing date14198455.917.12.2014
[2015/26]
Priority number, dateIN2013DEL367717.12.2013         Original published format: IN 3677DE2013
[2017/16]
Former [2015/26]IN2013DEL367717.12.2013
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2886544
Date:24.06.2015
Language:EN
[2015/26]
Type: B1 Patent specification 
No.:EP2886544
Date:21.11.2018
Language:EN
[2018/47]
Search report(s)(Supplementary) European search report - dispatched on:EP03.03.2015
ClassificationIPC:C07D487/04
[2015/26]
CPC:
C07D487/04 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/08]
Former [2015/26]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Verfahren zur Herstellung von kristallinem Sitagliptin-Fumarat[2015/26]
English:Process for the preparation of crystalline sitagliptin fumarate[2015/26]
French:Procédé de préparation de fumarate de sitagliptine sous forme cristalline[2015/26]
Examination procedure21.12.2015Amendment by applicant (claims and/or description)
04.01.2016Examination requested  [2016/08]
18.05.2017Despatch of a communication from the examining division (Time limit: M06)
26.10.2017Reply to a communication from the examining division
28.02.2018Communication of intention to grant the patent
03.07.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
31.08.2018Communication of intention to grant the patent
04.10.2018Fee for grant paid
04.10.2018Fee for publishing/printing paid
04.10.2018Receipt of the translation of the claim(s)
Opposition(s)22.08.2019No opposition filed within time limit [2019/44]
Fees paidRenewal fee
02.01.2017Renewal fee patent year 03
02.01.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL21.11.2018
AT21.11.2018
CY21.11.2018
CZ21.11.2018
DK21.11.2018
EE21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
MK21.11.2018
RO21.11.2018
RS21.11.2018
SE21.11.2018
SI21.11.2018
SK21.11.2018
SM21.11.2018
TR21.11.2018
MT17.12.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
[2020/31]
Former [2020/17]AL21.11.2018
AT21.11.2018
CZ21.11.2018
DK21.11.2018
EE21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RO21.11.2018
RS21.11.2018
SE21.11.2018
SI21.11.2018
SK21.11.2018
SM21.11.2018
TR21.11.2018
MT17.12.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2020/08]AL21.11.2018
AT21.11.2018
CZ21.11.2018
DK21.11.2018
EE21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RO21.11.2018
RS21.11.2018
SE21.11.2018
SI21.11.2018
SK21.11.2018
SM21.11.2018
MT17.12.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2019/50]AL21.11.2018
AT21.11.2018
CZ21.11.2018
DK21.11.2018
EE21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RO21.11.2018
RS21.11.2018
SE21.11.2018
SI21.11.2018
SK21.11.2018
SM21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2019/40]AL21.11.2018
AT21.11.2018
CZ21.11.2018
DK21.11.2018
EE21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RO21.11.2018
RS21.11.2018
SE21.11.2018
SK21.11.2018
SM21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2019/37]AL21.11.2018
AT21.11.2018
CZ21.11.2018
DK21.11.2018
EE21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RO21.11.2018
RS21.11.2018
SE21.11.2018
SM21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2019/35]AL21.11.2018
AT21.11.2018
CZ21.11.2018
DK21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RS21.11.2018
SE21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2019/34]AL21.11.2018
AT21.11.2018
DK21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RS21.11.2018
SE21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2019/26]AL21.11.2018
AT21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RS21.11.2018
SE21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
PT21.03.2019
Former [2019/25]AT21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
RS21.11.2018
SE21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
Former [2019/24]AT21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
SE21.11.2018
BG21.02.2019
NO21.02.2019
GR22.02.2019
IS21.03.2019
Former [2019/23]AT21.11.2018
FI21.11.2018
HR21.11.2018
LT21.11.2018
LV21.11.2018
BG21.02.2019
NO21.02.2019
IS21.03.2019
Former [2019/22]FI21.11.2018
LT21.11.2018
BG21.02.2019
NO21.02.2019
IS21.03.2019
Former [2019/21]FI21.11.2018
LT21.11.2018
NO21.02.2019
IS21.03.2019
Former [2019/20]LT21.11.2018
NO21.02.2019
Documents cited:Search[XDY]WO2009085990  (REDDYS LAB LTD DR [IN], et al) [XD] 16 * page 17, lines 5-9 * * page 23, line 19 - page 24, line 33 * * example 22 * [Y] 1-15;
 [XDY]WO2010000469  (RATIOPHARM GMBH [DE], et al) [XD] 16 * page 5, paragraph 2 * * page 6, paragraph 7 * * example 3 * [Y] 1-15;
 [XDY]US2010249140  (PILARSKI GIDEON [IL], et al) [XD] 16 * paragraph [0148] * * examples 21,22 * [Y] 1-15;
 [YA]WO2013084210  (RANBAXY LAB LTD [IN]) [Y] 1-15 * example 2 *[A] 16;
 [XDY]  - KIM DOOSEOP ET AL, "(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 48, doi:10.1021/JM0493156, ISSN 0022-2623, (20050101), pages 141 - 151, (20041213), XP002529729 [XD] 16 * page 148, paragraph last - page 149, paragraph first * [Y] 1-15

DOI:   http://dx.doi.org/10.1021/jm0493156
by applicantWO2004085661
 US7326708
 WO2009085990
 WO2010000469
 WO2010117738
 US2012142693
    - JOURNAL OF MEDICINAL CHEMISTRY, (2005), vol. 48, no. 1, pages 141 - 151
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.